troglitazone and Body Weight studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

Excerpt	Relevance	Reference
"This study was designed to assess the usefulness of a model-based index of insulin sensitivity during an oral glucose tolerance test (OGTT) in the identification of possible changes in this metabolic parameter produced by pharmacological agents known to be potent insulin sensitizers, that is metformin (M) and thiazolidinedione (T)."	9.12	Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. ( Hanusch-Enserer, U; Kautzky-Willer, A; Ludvik, B; Pacini, G; Prager, R; Tura, A; Wagner, OF; Winzer, C, 2006)
"To examine the tumor-promoting effect of troglitazone (TRG), a novel thiazolidinedione insulin-sensitizing agent, on splenic hemangiosarcomas in rasH2 mice, histopathological and molecular analyses were performed in the spleen of female rasH2 mice fed a diet containing 6,000 or 0 ppm TRG for 16 weeks after 1,000 or 0 mg/kg urethane (UR) initiation."	7.74	Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane. ( Dewa, Y; Hasumi, K; Jin, M; Matsumoto, S; Mitsumori, K; Nishimura, J; Saekusa, Y, 2008)
"Body weight and BP decreased significantly in the diet group but not in the troglitazone group at the end of the intervention periods."	7.71	Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. ( Kamide, K; Kawano, Y; Minami, J; Tsunoda, S, 2002)
"It is well known that troglitazone and voluntary running have the capacity to improve insulin resistance."	7.71	Effects of troglitazone and voluntary running on insulin resistance induced high fat diet in the rat. ( Han, YQ; Kitakoshi, K; Nakai, N; Oshida, Y; Sato, Y, 2001)
"Troglitazone is a new orally active hypoglycemic agent that has been shown to ameliorate insulin resistance and hyperinsulinemia in both diabetic animal models and non-insulin-dependent diabetes mellitus (NIDDM) subjects."	7.69	Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. ( Gao, KM; Khoursheed, M; Lee, MK; Miles, PD; Moossa, AR; Olefsky, JM, 1995)
"Troglitazone, a newly developed oral antidiabetic agent, improves hyperglycemia, and has been reported to improve insulin resistance and to decrease hepatic glucose production in diabetic animals."	7.69	Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance. ( Higa, S; Ishikawa, K; Mimura, G; Murakami, K; Takasu, N; Yagi, N, 1995)
"Treatment with troglitazone 400 mg q."	6.69	Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. ( Brinkmann, L; Goebel, FD; Michl, GM; Mühlbayer, D; Walli, R, 2000)
"Troglitazone treatment decreased adipose tissue GPX activity and abolished overproduction of TNF-alpha in OLETF rats."	5.31	Effect of obesity and troglitazone on expression of two glutathione peroxidases: cellular and extracellular types in serum, kidney and adipose tissue. ( Asayama, K; Dobashi, K; Hayashibe, H; Kodera, K; Nakane, T; Nakazawa, S; Uchida, N, 2001)
"Metformin-treated rats gained significantly less weight."	5.29	Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. ( Burant, CF; Polonsky, KS; Pugh, W; Sreenan, S; Sturis, J, 1996)
"This study was designed to assess the usefulness of a model-based index of insulin sensitivity during an oral glucose tolerance test (OGTT) in the identification of possible changes in this metabolic parameter produced by pharmacological agents known to be potent insulin sensitizers, that is metformin (M) and thiazolidinedione (T)."	5.12	Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. ( Hanusch-Enserer, U; Kautzky-Willer, A; Ludvik, B; Pacini, G; Prager, R; Tura, A; Wagner, OF; Winzer, C, 2006)
"Troglitazone treatment improved insulin sensitivity."	5.08	Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. ( Demacker, PN; Smits, P; Stalenhoef, AF; Tack, CJ, 1998)
"The object of this study is to evaluate the effects of age, gender, age-by-gender interaction, Type II diabetes, body weight, race, smoking, and formulation on steady-state pharmacokinetics of troglitazone, Metabolite 1 (sulfate conjugate), and Metabolite 3 (quinone metabolite) following multiple-dose oral administration of troglitazone."	4.79	Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. ( Abel, R; Alvey, CW; Koup, JR; Loi, CM; Randinitis, EJ; Young, MA, 1997)
"To examine the tumor-promoting effect of troglitazone (TRG), a novel thiazolidinedione insulin-sensitizing agent, on splenic hemangiosarcomas in rasH2 mice, histopathological and molecular analyses were performed in the spleen of female rasH2 mice fed a diet containing 6,000 or 0 ppm TRG for 16 weeks after 1,000 or 0 mg/kg urethane (UR) initiation."	3.74	Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane. ( Dewa, Y; Hasumi, K; Jin, M; Matsumoto, S; Mitsumori, K; Nishimura, J; Saekusa, Y, 2008)
"Recently, we found that profound anorexia observed in a catabolic model induced by chronic glucocorticoid (dexamethasone, Dex) injection could be associated with strong hyperleptinemia."	3.73	Troglitazone reduces leptinemia during experimental dexamethasone-induced stress. ( Caldefie-Chézet, F; Enreille-Leger, A; Poulin, A; Vasson, MP, 2005)
"Female CD-1 (ICR) mice were given a single intraperitoneal administration of AOM (10 mg/kg body weight) and followed by one-week oral exposure of 2% (w/v) DSS in drinking water, and then maintained on the basal diets mixed with or without nimesulide (0."	3.73	Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. ( Kohno, H; Sugie, S; Suzuki, R; Tanaka, T, 2005)
"Body weight and BP decreased significantly in the diet group but not in the troglitazone group at the end of the intervention periods."	3.71	Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. ( Kamide, K; Kawano, Y; Minami, J; Tsunoda, S, 2002)
" Compared with lean controls, untreated obese rats had significantly higher body weights, fat pad masses, plasma triglycerides, free fatty acids and leptin levels (for all P < 0."	3.71	Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. ( Doyle, PJ; Naderali, EK; Pickavance, LC; Wilding, JP; Williams, G, 2001)
"It is well known that troglitazone and voluntary running have the capacity to improve insulin resistance."	3.71	Effects of troglitazone and voluntary running on insulin resistance induced high fat diet in the rat. ( Han, YQ; Kitakoshi, K; Nakai, N; Oshida, Y; Sato, Y, 2001)
" In the present study, we examined the role of PPARgamma in angiotensin II (Ang II)-induced hypertrophy of neonatal rat cardiac myocytes and in pressure overload-induced cardiac hypertrophy of mice."	3.71	Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. ( Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H, 2002)
"To examine the effect of chronic oral administration of troglitazone on the age-related changes of insulin resistance, plasma CCK levels, and pancreatic growth in normal rats."	3.71	Troglitazone stimulates pancreatic growth in normal rats. ( Jia, DM; Otsuki, M, 2002)
" The aim was to define the insulin-sensitizing effects of S15261, the cleavage products, and troglitazone and metformin in the JCR:LA-cp rat, an animal model of the obesity/insulin resistance syndrome that exhibits an associated vasculopathy and cardiovascular disease."	3.70	Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat. ( Brindley, DN; Davidge, ST; Delrat, P; Jochemsen, R; Kelly, SE; O'Brien, SF; Pégorier, JP; Ravel, D; Russell, JC, 2000)
" We found that these rats exhibit reduced food intake and body weight gain associated with decreased hypothalamic neuropeptide Y (NPY) gene expression in the arcuate nucleus (ARC), both during ad-libitum feeding and after a 72-h fast."	3.70	Aging and the neuroendocrine regulation of reproduction and body weight. ( Gruenewald, DA; Marck, BT; Matsumoto, AM; Naai, MA; Wolden-Hanson, T, 2000)
"Both the lard and sucrose enrichment increased SBP and body weight compared with controls."	3.70	Dietary fat-induced increase in blood pressure and insulin resistance in rats. ( Hotta, N; Iguchi, A; Miura, H; Nakamura, J; Tamagawa, T; Tamaya, N; Uemura, K; Yoshioka, S, 2000)
"Troglitazone is a new orally active hypoglycemic agent that has been shown to ameliorate insulin resistance and hyperinsulinemia in both diabetic animal models and non-insulin-dependent diabetes mellitus (NIDDM) subjects."	3.69	Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. ( Gao, KM; Khoursheed, M; Lee, MK; Miles, PD; Moossa, AR; Olefsky, JM, 1995)
"Troglitazone, a newly developed oral antidiabetic agent, improves hyperglycemia, and has been reported to improve insulin resistance and to decrease hepatic glucose production in diabetic animals."	3.69	Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance. ( Higa, S; Ishikawa, K; Mimura, G; Murakami, K; Takasu, N; Yagi, N, 1995)
"Treatment with troglitazone 400 mg q."	2.69	Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. ( Brinkmann, L; Goebel, FD; Michl, GM; Mühlbayer, D; Walli, R, 2000)
"Patients with type 2 diabetes inadequately controlled on sulfonylurea can be effectively managed with a combination of troglitazone and sulfonylurea that is safe, well tolerated, and represents a new approach to achieving the glycemic targets recommended by the American Diabetes Association."	2.69	Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. ( Ghazzi, MN; Horton, ES; Venable, TC; Whitcomb, RW; Whitehouse, F, 1998)
"Troglitazone and metformin lower glucose levels in diabetic patients without increasing plasma insulin levels."	2.69	A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. ( Kruszynska, YT; Mulford, MI; Olefsky, JM; Yu, JG, 1999)
"There were 284 NIDDM patients (20-82 years of age) whose glycemic control while on a diet was judged stable but was judged unsatisfactory (fasting plasma glucose [FPG] > or = 8."	2.68	Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. ( Akanuma, Y; Iwamoto, Y; Kaneko, T; Kosaka, K; Kuzuya, T; Shigeta, Y, 1996)
"Treatment with troglitazone was found to increase whole-body insulin sensitivity in sucrose- and chow-fed rats, but had no effect on skeletal muscle glucose transport activity measured in isolated muscles from both dietary groups."	1.32	Effect of troglitazone on vascular and glucose metabolic actions of insulin in high-sucrose-fed rats. ( Bachelard, H; Nadeau, A; Pitre, M; Santuré, M, 2003)
"Troglitazone was less effective in controlling serum cholesterol and neuropathy."	1.31	Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. ( Kakimoto, K; Shibata, T; Takeuchi, S; Wakitani, K; Yokota, S; Yonemori, F, 2000)
"Troglitazone has been shown to improve insulin sensitivity and thereby exert hypoglycemic effects in various animal models and humans with insulin resistance and diabetes."	1.31	Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes. ( Akiyama, T; Fukumitsu, KI; Jia, DM; Nakamura, H; Otsuki, M; Tabaru, A, 2000)
"Troglitazone treatment was associated with increased citrate sensitivity of ACC."	1.31	Troglitazone stimulates acetyl-CoA carboxylase activity through a post-translational mechanism. ( Haas, MJ; Mooradian, AD; Thampy, GK, 2000)
"Troglitazone treatment decreased adipose tissue GPX activity and abolished overproduction of TNF-alpha in OLETF rats."	1.31	Effect of obesity and troglitazone on expression of two glutathione peroxidases: cellular and extracellular types in serum, kidney and adipose tissue. ( Asayama, K; Dobashi, K; Hayashibe, H; Kodera, K; Nakane, T; Nakazawa, S; Uchida, N, 2001)
"Troglitazone treatment produced a significant rise in the metabolic clearance rate of glucose (MCR) during the 6-mU/kg BW/min insulin clamp study (19."	1.30	Troglitazone improves insulin-stimulated glucose utilization associated with an increased muscle glycogen content in obese Zucker rats. ( Kako, M; Li, L; Nakai, N; Ohsawa, I; Oshida, Y; Sato, J; Sato, Y; Shimomura, Y, 1999)
"Troglitazone treatment decreased skeletal muscle, but not hepatic triglyceride and increased hepatic and muscle glycogen content in wild-type mice."	1.30	Troglitazone action is independent of adipose tissue. ( Burant, CF; Davidson, NO; Graves, RA; Hirano, K; Lohmiller, J; Lukens, J; Ross, S; Sreenan, S; Tai, TA, 1997)
"Troglitazone is a new oral antidiabetic agent and has been reported to reduce insulin resistance and improve peripheral hyperinsulinemia in patients with noninsulin-dependent diabetes mellitus."	1.30	Effect of troglitazone on blood insulin levels after pancreas transplantation with systemic venous drainage in rats. ( Mitsuo, M; Nakai, I; Oka, T; Shimizu, Y; Uchiyama, K; Yasunami, Y, 1997)
"Troglitazone appears to increase both glycogen and TG turnover in skeletal muscle."	1.30	Effects of troglitazone on substrate storage and utilization in insulin-resistant rats. ( Burant, CF; Cockburn, B; Fuller, T; Keck, S; Sreenan, S, 1999)
"Obesity is characterized by hyperinsulinemia, which reflects peripheral insulin resistance."	1.29	Antihypertensive effects of CS-045 treatment in obese Zucker rats. ( Fujiwara, T; Horikoshi, H; Ikeda, K; Koike, H; Nishino, H; Okuno, A; Shiraki, T; Wada, M; Yoshioka, S, 1993)
"Metformin-treated rats gained significantly less weight."	1.29	Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. ( Burant, CF; Polonsky, KS; Pugh, W; Sreenan, S; Sturis, J, 1996)
"Troglitazone treatment did not attenuate the insulinopenia and hyperglycemia of diabetic rats, but it partially improved the hypertriglyceridemia."	1.29	Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. ( Higa, S; Komiya, I; Nagamine, F; Shimabukuro, M; Shinzato, T; Takasu, N, 1996)

Research

Studies (61)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Percentage of Glycosylated Hemoglobin at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	19 (31.15)	18.2507
2000's	38 (62.30)	29.6817
2010's	4 (6.56)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Porcelli, L	1
Gilardi, F	1
Laghezza, A	1
Piemontese, L	1
Mitro, N	1
Azzariti, A	1
Altieri, F	1
Cervoni, L	1
Fracchiolla, G	1
Giudici, M	1
Guerrini, U	1
Lavecchia, A	1
Montanari, R	1
Di Giovanni, C	1
Paradiso, A	1
Pochetti, G	1
Simone, GM	1
Tortorella, P	1
Crestani, M	1
Loiodice, F	1
Palomba, L	1
Silvestri, C	1
Imperatore, R	1
Morello, G	1
Piscitelli, F	1
Martella, A	1
Cristino, L	1
Di Marzo, V	1
Jin, M	2
Saekusa, Y	2
Dewa, Y	2
Nishimura, J	2
Matsumoto, S	2
Shibutani, M	1
Hasumi, K	2
Mitsumori, K	2
Kakiuchi-Kiyota, S	2
Arnold, LL	2
Yokohira, M	2
Suzuki, S	2
Pennington, KL	2
Cohen, SM	2
Koza-Taylor, P	1
Varney, M	1
Tsunoda, S	1
Kamide, K	1
Minami, J	1
Kawano, Y	1
Mooradian, AD	2
Haas, MJ	2
Chehade, J	1
Wong, NC	1
Santuré, M	1
Pitre, M	1
Nadeau, A	1
Bachelard, H	1
Narce, M	1
Poisson, JP	1
Yotsumoto, T	1
Naitoh, T	1
Kanaki, T	1
Matsuda, M	1
Tsuruzoe, N	1
Asami-Miyagishi, R	1
Iseki, S	1
Usui, M	1
Uchida, K	1
Kubo, H	1
Morita, I	1
Caldefie-Chézet, F	1
Poulin, A	1
Enreille-Leger, A	1
Vasson, MP	1
Kohno, H	1
Suzuki, R	1
Sugie, S	1
Tanaka, T	1
Kautzky-Willer, A	1
Tura, A	1
Winzer, C	1
Wagner, OF	1
Ludvik, B	1
Hanusch-Enserer, U	1
Prager, R	1
Pacini, G	1
Khoursheed, M	1
Miles, PD	1
Gao, KM	1
Lee, MK	1
Moossa, AR	1
Olefsky, JM	2
Yoshioka, S	2
Nishino, H	1
Shiraki, T	1
Ikeda, K	1
Koike, H	1
Okuno, A	2
Wada, M	1
Fujiwara, T	2
Horikoshi, H	2
Yagi, N	1
Takasu, N	2
Higa, S	2
Ishikawa, K	1
Murakami, K	1
Mimura, G	1
Iwamoto, Y	1
Kosaka, K	1
Kuzuya, T	1
Akanuma, Y	2
Shigeta, Y	1
Kaneko, T	1
Shimabukuro, M	2
Shinzato, T	1
Nagamine, F	1
Komiya, I	1
Inoue, I	1
Takahashi, K	2
Katayama, S	1
Harada, Y	1
Negishi, K	1
Itabashi, A	1
Ishii, J	1
Sreenan, S	3
Sturis, J	1
Pugh, W	1
Burant, CF	3
Polonsky, KS	1
Hirano, K	1
Tai, TA	1
Lohmiller, J	1
Lukens, J	1
Davidson, NO	1
Ross, S	1
Graves, RA	1
Uchiyama, K	1
Nakai, I	1
Shimizu, Y	1
Mitsuo, M	1
Yasunami, Y	1
Oka, T	1
Tamemoto, H	1
Tobe, K	1
Ueki, K	1
Mori, Y	1
Iwamoto, K	1
Umesono, K	1
Yazaki, Y	1
Kadowaki, T	2
Loi, CM	1
Alvey, CW	1
Randinitis, EJ	1
Abel, R	1
Young, MA	1
Koup, JR	1
Tack, CJ	1
Smits, P	1
Demacker, PN	1
Stalenhoef, AF	1
Horton, ES	1
Whitehouse, F	1
Ghazzi, MN	1
Venable, TC	1
Whitcomb, RW	1
Qiang, X	1
Satoh, J	1
Sagara, M	1
Fukuzawa, M	1
Masuda, T	1
Sakata, Y	1
Muto, G	1
Muto, Y	1
Toyota, T	1
Kelly, IE	1
Han, TS	1
Walsh, K	2
Lean, ME	1
Keck, S	1
Fuller, T	1
Cockburn, B	1
Higa, M	2
Zhou, YT	2
Ravazzola, M	1
Baetens, D	2
Orci, L	2
Unger, RH	2
Yu, JG	1
Kruszynska, YT	1
Mulford, MI	1
Mizushige, K	1
Noma, T	1
Yao, L	1
Yu, Y	1
Kiyomoto, H	1
Hosomi, N	1
Fukui, T	1
Kimura, S	1
Abe, Y	1
Matsuo, H	1
Oshida, Y	2
Kako, M	1
Nakai, N	2
Shimomura, Y	1
Li, L	1
Sato, J	1
Ohsawa, I	1
Sato, Y	3
Grayburn, P	1
Karim, A	1
Walli, R	1
Michl, GM	1
Mühlbayer, D	1
Brinkmann, L	1
Goebel, FD	1
Shibata, T	1
Takeuchi, S	1
Yokota, S	1
Kakimoto, K	1
Yonemori, F	1
Wakitani, K	1
King, AB	1
Jia, DM	2
Tabaru, A	1
Nakamura, H	1
Fukumitsu, KI	1
Akiyama, T	1
Otsuki, M	2
Russell, JC	1
Ravel, D	1
Pégorier, JP	1
Delrat, P	1
Jochemsen, R	1
O'Brien, SF	1
Kelly, SE	1
Davidge, ST	1
Brindley, DN	1
Chicco, A	1
Basabe, JC	1
Karabatas, L	1
Ferraris, N	1
Fortino, A	1
Lombardo, YB	1
Fujiwara, K	1
Hayashi, K	1
Ozawa, Y	1
Tokuyama, H	1
Nakamura, A	1
Saruta, T	1
Matsumoto, AM	1
Marck, BT	1
Gruenewald, DA	1
Wolden-Hanson, T	1
Naai, MA	1
McCarthy, KJ	1
Routh, RE	1
Shaw, W	1
Welbourne, TC	1
Johnson, JH	1
Oberkofler, H	1
Neschen, S	1
Esterbauer, H	1
Waldhäusl, W	2
Patsch, W	1
Fürnsinn, C	2
Suzuki, A	1
Yasuno, T	1
Kojo, H	1
Hirosumi, J	1
Mutoh, S	1
Notsu, Y	1
Uemura, K	1
Tamaya, N	1
Tamagawa, T	1
Miura, H	1
Iguchi, A	1
Nakamura, J	1
Hotta, N	1
Young, ME	1
Goodwin, GW	1
Ying, J	1
Guthrie, P	1
Wilson, CR	1
Laws, FA	1
Taegtmeyer, H	1
Thampy, GK	1
Aoki, K	1
Kikuchi, T	1
Mukasa, K	1
Ito, S	1
Nakajima, A	1
Satoh, S	1
Okamura, A	1
Sekihara, H	1
Collins, AR	1
Meehan, WP	1
Kintscher, U	1
Jackson, S	1
Wakino, S	1
Noh, G	1
Palinski, W	1
Hsueh, WA	1
Law, RE	1
Chen, Z	1
Ishibashi, S	1
Perrey, S	1
Gotoda, T	1
Kitamine, T	1
Tamura, Y	1
Okazaki, H	1
Yahagi, N	1
Iizuka, Y	1
Shionoiri, F	1
Ohashi, K	1
Harada, K	1
Shimano, H	1
Nagai, R	1
Yamada, N	1
Naderali, EK	1
Pickavance, LC	1
Wilding, JP	1
Doyle, PJ	1
Williams, G	1
Asayama, K	1
Nakane, T	1
Dobashi, K	1
Kodera, K	1
Hayashibe, H	1
Uchida, N	1
Nakazawa, S	1
Kitakoshi, K	1
Han, YQ	1
Hayashi, H	1
Kanai, S	1
Ichikawa, M	1
Funakoshi, A	1
Miyasaka, K	1
Nowotny, P	1
Brunmair, B	1
Gras, F	1
Roden, M	1
Vierhapper, H	1
Asakawa, M	1
Takano, H	1
Nagai, T	1
Uozumi, H	1
Hasegawa, H	1
Kubota, N	1
Saito, T	1
Masuda, Y	1
Komuro, I	1
Yamashita, H	1
Nagai, Y	1
Takamura, T	1
Nohara, E	1
Kobayashi, K	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy of Leptin Replacement in Treatment of Lipodystrophy[NCT00005905]	Phase 2	20 participants	Interventional	2000-06-30	Completed
Long-Term Efficacy of Leptin Replacement in Treatment of Lipodystrophy[NCT00025883]	Phase 2	103 participants (Actual)	Interventional	2001-10-31	Completed
Quantification of Intramyocardial Lipid by Proton Magnetic Resonance Spectroscopy[NCT00469911]		18 participants (Actual)	Interventional	2005-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Percentage of glycosylated hemoglobin at Baseline, 6 months, and 12 months on treatment with metreleptin (NCT00025883)
Timeframe: Baseline, 6 months, 12 months

Triglycerides at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin

Correlation Co-efficient Between MRS Spectroscopy and Endomyocardial Biopsy in Heart Transplant Participants

Intervention	percentage of glycated hemoglobin (Mean)
	Baseline	6 months	12 months
Generalized Lipodystrophy (GLD)	8.4	6.6	6.4
Partial Lipodystrophy (PLD)	8.1	7.2	7.3

Intervention	mg/dL (Geometric Mean)
	Baseline	6 months	12 months
Generalized Lipodystrophy (GLD)	467	198	180
Partial Lipodystrophy (PLD)	483	339	326

Participants first had MRS spectroscopy then the MRS spectroscopy images were compared to endomyocardial biopsy (NCT00469911)
Timeframe: 2 to 10 days

Article	Year
Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:5 Topics: Blood Glucose; Body Weight; C-Peptide; Cell Adhesion Molecules; Chromans; Diabetes Mellitus, Type 2;	2006
Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes care, 1996, Volume: 19, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Body Weight; Cholesterol; Chromans; Diabetes Mellitu	1996
Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes care, 1998, Volume: 21, Issue:5 Topics: Adult; Blood Glucose; Body Weight; Cholesterol, LDL; Chromans; Cross-Over Studies; Double-Blind Meth	1998
Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes care, 1998, Volume: 21, Issue:9 Topics: Blood Glucose; Body Weight; C-Peptide; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Dru	1998
Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes care, 1999, Volume: 22, Issue:2 Topics: Abdomen; Adipose Tissue; Adult; Aged; Body Weight; Calibration; Chromans; Double-Blind Method; Femal	1999
A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes, 1999, Volume: 48, Issue:12 Topics: Blood Glucose; Body Weight; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Ci	1999
Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie, 2000, Volume: 199, Issue:5 Topics: Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus; HIV	2000
A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes care, 2000, Volume: 23, Issue:4 Topics: Body Weight; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemoglob	2000

Article	Year
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity. Journal of medicinal chemistry, 2012, Jan-12, Volume: 55, Issue:1 Topics: Adipocytes; Animals; Antineoplastic Agents; Benzoxazoles; Body Weight; Calorimetry; Cell Differentia	2012
Negative Regulation of Leptin-induced Reactive Oxygen Species (ROS) Formation by Cannabinoid CB1 Receptor Activation in Hypothalamic Neurons. The Journal of biological chemistry, 2015, May-29, Volume: 290, Issue:22 Topics: Adipocytes; Animals; Animals, Newborn; Arachidonic Acids; Benzamides; Body Weight; Cannabinoids; Cat	2015
Hepatocarcinogenic susceptibility of rasH2 mice to troglitazone in a two-stage hepatocarcinogenesis model. Archives of toxicology, 2009, Volume: 83, Issue:2 Topics: Animals; Biomarkers, Tumor; Body Weight; Carcinogens; Chromans; Disease Models, Animal; Disease Susc	2009
Evaluation of PPARγ agonists on rodent endothelial cell proliferation. Toxicology, 2011, Sep-05, Volume: 287, Issue:1-3 Topics: Adipose Tissue; Animals; Apoptosis; Body Weight; Cell Proliferation; Chromans; DNA; Endothelial Cell	2011
Evaluation of direct and indirect effects of the PPARγ agonist troglitazone on mouse endothelial cell proliferation. Toxicologic pathology, 2011, Volume: 39, Issue:7 Topics: Adipose Tissue; Animals; Antineoplastic Agents; Body Weight; Cell Growth Processes; Cell Hypoxia; Ce	2011
Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. American journal of hypertension, 2002, Volume: 15, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Body Weight; Caloric Restriction; Chroma	2002
Apolipoprotein A-I expression in rats is not altered by troglitazone. Experimental biology and medicine (Maywood, N.J.), 2002, Volume: 227, Issue:11 Topics: Animals; Apolipoprotein A-I; Body Weight; Chromans; Gene Expression Regulation; Male; Rats; Rats, In	2002
Effect of troglitazone on vascular and glucose metabolic actions of insulin in high-sucrose-fed rats. Metabolism: clinical and experimental, 2003, Volume: 52, Issue:8 Topics: Animals; Biological Transport, Active; Blood Pressure; Blood Vessels; Body Weight; Chromans; Diet; E	2003
Novel PPARgamma-dependent and independent effects for thiazolidinediones. Current opinion in lipidology, 2003, Volume: 14, Issue:6 Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Ins	2003
A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation. Metabolism: clinical and experimental, 2003, Volume: 52, Issue:12 Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body	2003
Expression and function of PPARgamma in rat placental development. Biochemical and biophysical research communications, 2004, Mar-05, Volume: 315, Issue:2 Topics: Administration, Oral; Animals; Body Weight; Cell Differentiation; Chromans; DNA; Ear, Inner; Female;	2004
Troglitazone reduces leptinemia during experimental dexamethasone-induced stress. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2005, Volume: 37, Issue:3 Topics: Adipocytes; Adipose Tissue; Animals; Anorexia; Blood Glucose; Body Weight; Chemical and Drug Induced	2005
Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC cancer, 2005, May-16, Volume: 5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Bezafibrate; Body Weight; Chromans; Col	2005
Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane. Archives of toxicology, 2008, Volume: 82, Issue:10 Topics: Angiogenic Proteins; Animals; Body Weight; Carcinogens; Cell Proliferation; Chromans; Female; Gene E	2008
Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. Metabolism: clinical and experimental, 1995, Volume: 44, Issue:11 Topics: Animals; Blood Pressure; Body Weight; Chromans; Dietary Fats; Eating; Glucose; Glucose Clamp Techniq	1995
Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism: clinical and experimental, 1993, Volume: 42, Issue:1 Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Chromans; Diuresis; Fe	1993
Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1995, Volume: 27, Issue:10 Topics: Aging; Animals; Blood Glucose; Body Weight; Chromans; Fructose; Hyperinsulinism; Hypoglycemic Agents	1995
Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism: clinical and experimental, 1996, Volume: 45, Issue:9 Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus, Experimental; Heart;	1996
Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and beta-oxidation in fructose-fed rats. Metabolism: clinical and experimental, 1995, Volume: 44, Issue:12 Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Chromans; Diet; Drug Tolerance; Fatty Acids, Nones	1995
Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. The American journal of physiology, 1996, Volume: 271, Issue:4 Pt 1 Topics: Age Factors; Animals; Body Weight; Chromans; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified;	1996
Troglitazone action is independent of adipose tissue. The Journal of clinical investigation, 1997, Dec-01, Volume: 100, Issue:11 Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus, Type	1997
Troglitazone action is independent of adipose tissue. The Journal of clinical investigation, 1997, Dec-01, Volume: 100, Issue:11 Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus, Type	1997
Troglitazone action is independent of adipose tissue. The Journal of clinical investigation, 1997, Dec-01, Volume: 100, Issue:11 Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus, Type	1997
Troglitazone action is independent of adipose tissue. The Journal of clinical investigation, 1997, Dec-01, Volume: 100, Issue:11 Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus, Type	1997
Effect of troglitazone on blood insulin levels after pancreas transplantation with systemic venous drainage in rats. Transplantation, 1997, Nov-27, Volume: 64, Issue:10 Topics: Animals; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus, Type 1; Drainage; Glucose Toleranc	1997
Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. The Journal of clinical investigation, 1998, Mar-15, Volume: 101, Issue:6 Topics: Adipocytes; Adipose Tissue; Animals; Apoptosis; Blood Glucose; Blotting, Northern; Body Weight; Chro	1998
Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetologia, 1998, Volume: 41, Issue:11 Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus, Experimental; Diabet	1998
Effects of troglitazone on substrate storage and utilization in insulin-resistant rats. The American journal of physiology, 1999, Volume: 276, Issue:6 Topics: Animals; Body Weight; Chromans; Eating; Glucose; Glycogen; In Vitro Techniques; Insulin; Insulin Res	1999
Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proceedings of the National Academy of Sciences of the United States of America, 1999, Sep-28, Volume: 96, Issue:20 Topics: Animals; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus; Eating; Hypoglycemic Agents; Islet	1999
Effects of troglitazone on collagen accumulation and distensibility of aortic wall in prestage of non-insulin-dependent diabetes mellitus of Otsuka Long-Evans Tokushima Fatty rats. Journal of cardiovascular pharmacology, 2000, Volume: 35, Issue:1 Topics: Animals; Aorta, Thoracic; Body Weight; Chromans; Collagen; Diabetes Mellitus, Type 2; Glucose Tolera	2000
Troglitazone improves insulin-stimulated glucose utilization associated with an increased muscle glycogen content in obese Zucker rats. Endocrine journal, 1999, Volume: 46, Issue:5 Topics: 3-Hydroxyacyl CoA Dehydrogenases; Animals; Blood Glucose; Body Weight; Chromans; Eating; Glucose Cla	1999
Lipotoxic heart disease in obese rats: implications for human obesity. Proceedings of the National Academy of Sciences of the United States of America, 2000, Feb-15, Volume: 97, Issue:4 Topics: Age Factors; Animals; Apoptosis; Blood Glucose; Body Weight; Chromans; DNA Fragmentation; Echocardio	2000
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. British journal of pharmacology, 2000, Volume: 130, Issue:3 Topics: Absorptiometry, Photon; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Cataract; Chro	2000
Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes. Metabolism: clinical and experimental, 2000, Volume: 49, Issue:9 Topics: Adipose Tissue; Aging; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus	2000
Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat. The Journal of pharmacology and experimental therapeutics, 2000, Volume: 295, Issue:2 Topics: Animals; Blood Glucose; Body Weight; Chromans; Eating; Fluorenes; Gene Expression; Glucose Tolerance	2000
Troglitazone (CS-045) normalizes hypertriglyceridemia and restores the altered patterns of glucose-stimulated insulin secretion in dyslipidemic rats. Metabolism: clinical and experimental, 2000, Volume: 49, Issue:10 Topics: Animals; Body Weight; Chromans; Dietary Sucrose; Fatty Acids, Nonesterified; Glucose; Hypertriglycer	2000
Renal protective effect of troglitazone in Wistar fatty rats. Metabolism: clinical and experimental, 2000, Volume: 49, Issue:10 Topics: Animals; Blood Pressure; Body Weight; Chromans; Female; Hypoglycemic Agents; Insulin Resistance; Kid	2000
Aging and the neuroendocrine regulation of reproduction and body weight. Experimental gerontology, 2000, Volume: 35, Issue:9-10 Topics: Aging; Animals; Arcuate Nucleus of Hypothalamus; Body Composition; Body Weight; Chromans; Eating; Ge	2000
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney international, 2000, Volume: 58, Issue:6 Topics: Animals; Basement Membrane; Body Weight; Chondroitin Sulfate Proteoglycans; Chromans; Diabetes Melli	2000
UCP3 gene expression does not correlate with muscle oxidation rates in troglitazone-treated Zucker fatty rats. Biochimica et biophysica acta, 2000, Dec-15, Volume: 1517, Issue:1 Topics: Animals; Antioxidants; Body Weight; Carbon Dioxide; Carrier Proteins; Chromans; Diabetes Mellitus, T	2000
Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones. Japanese journal of pharmacology, 2000, Volume: 84, Issue:2 Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus, Experimental; Female;	2000
Dietary fat-induced increase in blood pressure and insulin resistance in rats. Journal of hypertension, 2000, Volume: 18, Issue:12 Topics: Adipose Tissue; Animals; Blood Glucose; Blood Pressure; Body Weight; Chromans; Dietary Carbohydrates	2000
Regulation of cardiac and skeletal muscle malonyl-CoA decarboxylase by fatty acids. American journal of physiology. Endocrinology and metabolism, 2001, Volume: 280, Issue:3 Topics: Animals; Aorta; Blood Pressure; Body Weight; Carboxy-Lyases; Chromans; Constriction; Diabetes Mellit	2001
Troglitazone stimulates acetyl-CoA carboxylase activity through a post-translational mechanism. Life sciences, 2000, Dec-29, Volume: 68, Issue:6 Topics: Acetyl-CoA Carboxylase; Animals; Body Weight; Chromans; Eating; Hypoglycemic Agents; Indicators and	2000
Dehydroepiandrosterone suppresses elevated hepatic glucose-6-phosphatase mRNA level in C57BL/KsJ-db/db mice: comparison with troglitazone. Endocrine journal, 2000, Volume: 47, Issue:6 Topics: Animals; Blood Glucose; Blotting, Northern; Body Weight; Chromans; Dehydroepiandrosterone; Diabetes	2000
Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arteriosclerosis, thrombosis, and vascular biology, 2001, Volume: 21, Issue:3 Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aorta; Arteriosclerosis; Blood Glu	2001
Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arteriosclerosis, thrombosis, and vascular biology, 2001, Volume: 21, Issue:3 Topics: Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Blood Glucose; Blotting, Northern; Body Weight;	2001
Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. European journal of pharmacology, 2001, Mar-23, Volume: 416, Issue:1-2 Topics: Acetylcholine; Animals; Blood Glucose; Body Weight; Chromans; Diet; Dose-Response Relationship, Drug	2001
Effect of obesity and troglitazone on expression of two glutathione peroxidases: cellular and extracellular types in serum, kidney and adipose tissue. Free radical research, 2001, Volume: 34, Issue:4 Topics: Adipose Tissue; Animals; Blood Glucose; Blotting, Western; Body Weight; Chromans; Enzyme-Linked Immu	2001
Effects of troglitazone and voluntary running on insulin resistance induced high fat diet in the rat. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2001, Volume: 33, Issue:6 Topics: Animals; Blood Glucose; Body Weight; Chromans; Dietary Fats; Female; Glucose; Glucose Clamp Techniqu	2001
Increased lymphatic lipid transport in genetically diabetic obese rats. American journal of physiology. Gastrointestinal and liver physiology, 2002, Volume: 282, Issue:1 Topics: Animals; Bile Acids and Salts; Body Weight; Carrier Proteins; Chromans; Diabetes Mellitus; Diabetes	2002
Thiazolidinediones influence plasma steroids of male obese Zucker rats. Endocrinology, 2002, Volume: 143, Issue:1 Topics: Animals; Blood Glucose; Body Weight; Chromans; Glucose; Hormones; Insulin; Male; Muscle, Skeletal; O	2002
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation, 2002, Mar-12, Volume: 105, Issue:10 Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Ce	2002
Troglitazone stimulates pancreatic growth in normal rats. Pancreas, 2002, Volume: 24, Issue:3 Topics: Aging; Alanine Transaminase; Amylases; Animals; Aspartate Aminotransferases; Blood Glucose; Body Wei	2002
Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism: clinical and experimental, 2002, Volume: 51, Issue:4 Topics: Albuminuria; Animals; Basement Membrane; Blood Glucose; Blood Pressure; Body Weight; Chromans; Creat	2002

troglitazone and Body Weight